A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy
暂无分享,去创建一个
K. Haustermans | E. Van Cutsem | S. Tejpar | G. De Meerleer | C. Draulans | J. Dekervel | M. Oražem | M. Spaas | M. Debecker
[1] Joe Y. Chang,et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.
[2] R. Weichselbaum,et al. Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite” , 2020, Clinical Cancer Research.
[3] R. Bell,et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance , 2019, Journal of Immunotherapy for Cancer.
[4] L. Apetoh,et al. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response , 2019, Cancers.
[5] C. Fuller,et al. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. , 2019, JAMA oncology.
[6] Michael Lock,et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.
[7] A. Grosu,et al. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries , 2019, Strahlentherapie und Onkologie.
[8] J. Gong,et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination , 2018, Journal of Immunotherapy for Cancer.
[9] R. Stupp,et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. , 2017, Cancer treatment reviews.
[10] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[11] C. Drake,et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.
[12] B. Loo,et al. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.
[13] S. Ashley,et al. Immunocompromised status in patients with necrotizing soft-tissue infection. , 2013, JAMA surgery.
[14] A. Shinagare,et al. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. , 2012, AJR. American journal of roentgenology.
[15] J. Vogel,et al. Enterocutaneous fistula associated with malignancy and prior radiation therapy. , 2010, Clinics in colon and rectal surgery.
[16] J. Sonke,et al. Normal Tissue Complication Probability after hypofractionation increased due to the high dose per fraction or the high total Biological Equivalent Dose? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] Shenhong Wu,et al. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. , 2009, The Lancet. Oncology.
[18] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Berlin,et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.